Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 1/20 | 0.46 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.43 |
| ▸ | USP2 | O75604 | 4/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.43 |
| ▸ | CLK4 | Q9HAZ1 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | NPR1 | P16066 | 6/20 | 0.42 |
| ▸ | AVPR1B | P47901 | 2/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4168721 | 0.89 | NPR1 (0.48) | EGLN1NPR1AVPR1B | |
| SCHEMBL4186187 | 0.88 | NPR1 (0.45) | EGLN1USP2CYP1A2CLK4LMNA | |
| SCHEMBL4182349 | 0.88 | LMNA (0.53) | EGLN1USP2CYP1A2CLK4LMNA | |
| SCHEMBL4184720 | 0.87 | NSD2 (0.49) | NSD2NPR1 | |
| SCHEMBL4180714 | 0.87 | EGLN1 (0.44) | NSD2EGLN1USP2CYP1A2CLK4 | |
| SCHEMBL4178085 | 0.86 | APP (0.47) | EGLN1NPR1AVPR1B | |
| SCHEMBL4188225 | 0.86 | TLR7 (0.50) | EGLN1USP2CYP1A2CLK4LMNA | |
| SCHEMBL4173222 | 0.86 | NSD2 (0.49) | NSD2EGLN1USP2CYP1A2CLK4 | |
| SCHEMBL4177505 | 0.86 | NPR1 (0.44) | EGLN1USP2CYP1A2CLK4LMNA | |
| SCHEMBL4184947 | 0.85 | PDE5A (0.47) | EGLN1USP2CYP1A2CLK4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069320-A1 | Substituted 4-Amino-Quinazoline Compounds with Metabotropic Glutamate Receptor Regulating Activity and Uses Thereof | GRUENENTHAL GMBH (DE) | 2009-03-12 | — | — | US | claimed |
| EP-1996562-A1 | SUBSTITUTED 4-AMINO-QUINAZOLINE DERIVATIVES AS REGULATORS OF METABOTROPIC GLUTAMATE RECEPTORS AND THEIR USE FOR PRODUCING DRUGS | Grünenthal GmbH (DE) | 2008-12-03 | — | — | EP | claimed |
| WO-2007104560-A1 | SUBSTITUTED 4-AMINO-QUINAZOLINE DERIVATIVES AS REGULATORS OF METABOTROPIC GLUTAMATE RECEPTORS AND THEIR USE FOR PRODUCING DRUGS | Grünenthal GmbH (DE) | 2007-09-20 | — | — | WO | claimed |
| US-20090069320-A1 | Substituted 4-Amino-Quinazoline Compounds with Metabotropic Glutamate Receptor Regulating Activity and Uses Thereof | GRUENENTHAL GMBH (DE) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069320-A1 | Substituted 4-Amino-Quinazoline Compounds with Metabotropic Glutamate Receptor Regulating Activity and Uses Thereof | GRM1, GRIN1, GRM2 | NSD2 3412/4885EGLN1 1486/4885USP2 2425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.